Evidence map›Paper›PMID 19915017›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2010

Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus.

J T Jonker, H J Lamb, R W van der Meer, L J Rijzewijk, L J Menting, M Diamant, J J Bax, A de Roos, J A Romijn, J W A Smit

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01761318 (Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761318 phase4completedstarted 2013, after this paper: background citation

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus

Ran2013Enrolled50Registered outcomes48Posted comparisons0ConditionsCardiovascular Disease, Diabetes Mellitus Type 2, Diastolic Dysfunction, Fatty LiverArmsliraglutide, Liraglutide - Placebo
PMID 16776751PMID 18819705PMID 19349323PMID 19930006PMID 11997279PMID 19815124PMID 20609967PMID 22586279PMID 22723560PMID 22949540PMID 19540343PMID 19317822other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.Handbook of experimental pharmacology · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Clinical importance of epicardial adipose tissue.Archives of medical science : AMS · 2017 · on this map
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

J T JonkerDepartments of Endocrinology and Metabolism, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. j.t.jonker@lumc.nl
H J Lamb
R W van der Meer
L J Rijzewijk
L J Menting
M Diamant
J J Bax
A de Roos
J A Romijn
J W A Smit
Leiden University Medical Center · NLVrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextPeroxisome proliferator-activated receptor-gamma agonists are involved in fat cell differentiation.

objectiveThe objective of the study was to investigate the effect of pioglitazone vs. metformin on pericardial fat volume in type 2 diabetic (T2DM) patients. Furthermore, we aimed to assess the relationship between pericardial fat volume, other fat compartments, and myocardial function at baseline and after treatment.

designThis was a prospective, randomized, double-blind, intervention study.

settingThe study was conducted at a university hospital. PATIENTS: Patients included 78 men with T2DM (aged 56.5 +/- 0.6 yr; glycosylated hemoglobin 7.1 +/- 0.1%) without structural heart disease.

interventionPatients were randomly assigned to pioglitazone (30 mg/d) or metformin (2000 mg/d) and matching placebo during 24 wk.

main outcome measuresPericardial and abdominal fat volumes and myocardial left ventricular function were measured by magnetic resonance imaging and hepatic and myocardial triglyceride content by proton magnetic resonance spectroscopy.

resultsPioglitazone increased pericardial fat volume [30.5 +/- 1.7 ml (baseline) vs. 33.1 +/- 1.8 ml], whereas metformin did not affect pericardial fat volume (29.2 +/- 1.5 ml vs. 29.6 +/- 1.6 ml, between groups P = 0.02). After correction for body mass index and age, only visceral fat volume correlated with pericardial fat volume at baseline (r = 0.55, P < 0.001). The increase in pericardial fat volume induced by pioglitazone was not associated with a decrease in left ventricular diastolic function.

conclusionIn T2DM patients, pioglitazone increases pericardial fat volume. This increase in pericardial fat volume did not negatively affect myocardial function after 24 wk. These observations question the notion of an inverse causal relationship between pericardial fat volume and myocardial function.

Indexed as

Abdominal FatAdipose TissueAgedDiabetes Mellitus, Type 2Double-Blind MethodHumansHypoglycemic AgentsMaleMetforminMiddle AgedOrgan SizePericardiumPioglitazonePlacebosThiazolidinedionesHypoglycemic AgentsMetforminPioglitazonePlacebosThiazolidinediones

Identifiers

PMID19915017
OpenAlexW1976143502

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.